Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies?

Recent years have seen great advancements in genome editing technologies, allowing for efficient and specific targeting of DNA sequences into the genome. In parallel, advancements in stem cell research, and especially the ability to induce pluripotency in somatic cells, have brought stem cell-derive...

Descripción completa

Detalles Bibliográficos
Autor principal: Ben-David, Uri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448953/
https://www.ncbi.nlm.nih.gov/pubmed/26056569
http://dx.doi.org/10.1186/2052-8426-1-3
_version_ 1782373792890224640
author Ben-David, Uri
author_facet Ben-David, Uri
author_sort Ben-David, Uri
collection PubMed
description Recent years have seen great advancements in genome editing technologies, allowing for efficient and specific targeting of DNA sequences into the genome. In parallel, advancements in stem cell research, and especially the ability to induce pluripotency in somatic cells, have brought stem cell-derived therapies closer to the clinic. In this commentary, I envision how groundbreaking genome editing technologies will influence stem cell biology research, paving the way to regenerative medicine with genetically engineered cells.
format Online
Article
Text
id pubmed-4448953
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44489532015-06-09 Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies? Ben-David, Uri Mol Cell Ther Commentary Recent years have seen great advancements in genome editing technologies, allowing for efficient and specific targeting of DNA sequences into the genome. In parallel, advancements in stem cell research, and especially the ability to induce pluripotency in somatic cells, have brought stem cell-derived therapies closer to the clinic. In this commentary, I envision how groundbreaking genome editing technologies will influence stem cell biology research, paving the way to regenerative medicine with genetically engineered cells. BioMed Central 2013-11-06 /pmc/articles/PMC4448953/ /pubmed/26056569 http://dx.doi.org/10.1186/2052-8426-1-3 Text en © Ben-David; licensee BioMed Central Ltd. 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Ben-David, Uri
Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies?
title Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies?
title_full Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies?
title_fullStr Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies?
title_full_unstemmed Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies?
title_short Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies?
title_sort flowing through the crispr-cascade: will genome editing boost cell therapies?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448953/
https://www.ncbi.nlm.nih.gov/pubmed/26056569
http://dx.doi.org/10.1186/2052-8426-1-3
work_keys_str_mv AT bendaviduri flowingthroughthecrisprcascadewillgenomeeditingboostcelltherapies

Ejemplares similares